Jason Broderick

Articles

Apalutamide Plus ADT Elicits PSA PFS Benefit in High-Risk, Biochemically Relapsed Prostate Cancer

September 11th 2022

Intensification of androgen-deprivation therapy plus apalutamide displayed promising efficacy in patients with high-risk, biochemically relapsed prostate cancer.

Atezolizumab Fails to Improve DFS in RCC Following Resection

September 10th 2022

Treatment with atezolizumab did not improve clinical outcomes vs placebo following resection in patients with renal cell carcinoma at increased risk of recurrence.

Select Biomarkers Signal Worse Survival Outcomes With Apalutamide/ADT in mCSPC

June 7th 2022

Circulating tumor DNA, select androgen receptor, and non-AR biomarkers have been identified as potential prognostic indicators of overall survival benefit for apalutamide plus androgen-deprivation therapy for patients with metastatic castration-sensitive prostate cancer.

PSMA-PET Imaging Parameters Shown to Identify Optimal Population for 177Lu-PSMA-617 Treatment in mCRPC

June 6th 2022

68Ga-PSMA-11 PET/CT imaging parameters demonstrated a statistically significant association with clinical outcomes with the PSMA-targeted radioligand therapy lutetium-PSMA-617 in patients with metastatic castration-resistant prostate cancer.

TMB Serves as Predictive Biomarker of Toripalimab Efficacy in Urothelial Carcinoma

June 4th 2022

Tumor mutational burden served as a prognostic indicator of the efficacy of toripalimab among Chinese patients with urothelial carcinoma.

Atezolizumab Plus Cabozantinib Elicits Clinical Activity in Advanced Urothelial Cancer

June 4th 2022

Cabozantinib plus atezolizumab demonstrated promising clinical activity and a suitable safety profile as first-line therapy in patients with cisplatin- eligible and -ineligible, inoperable locally advanced or metastatic urothelial cancer and as second- or later-line therapy in those who received a prior immune checkpoint inhibitor, according to findings from the phase 1b COSMIC-021 trial.

Neoadjuvant Axitinib Effective in Subgroup of Patients with Renal Cell Carcinoma

May 16th 2022

Neoadjuvant axitinib facilitated partial nephrectomy in patients with clear cell renal cell carcinoma and complex masses with an imperative indication for nephron-sparing surgery but no viable pathway to receive the procedure.

Darolutamide Demonstrates Strong Safety Profile in mCRPC after Long-Term Analyses

February 18th 2022

Darolutamide produced a well-tolerated safety profile in patients with metastatic castration-resistant prostate cancer, according to pooled data from long-term analyses of 3 trials.

Olaparib Plus Bipolar Androgen Therapy Showcases Clinical Activity Within Prostate Cancer

September 17th 2021

Combining the PARP inhibitor olaparib with bipolar androgen therapy demonstrated promising clinical activity in patients with castration-resistant prostate cancer.

TAK-700 Plus ADT Significantly Improves PFS and PSA Responses in mHSPC, But Not OS

June 8th 2021

The addition of TAK-700 to androgen-deprivation therapy improved median progression-free survival and prostate-specific antigen responses, but did not significantly improve overall survival vs ADT and bicalutamide in patients with newly diagnosed metastatic hormone-sensitive prostate cancer.

TURBT Plus Nivolumab/Chemo Shows Promise in Muscle-Invasive Bladder Cancer

June 8th 2021

Combining transurethral resection of the bladder tumor with nivolumab and chemotherapy showed promise as a bladder-sparing treatment strategy in patients with muscle-invasive bladder cancer.

Pembrolizumab/Axitinib Survival Benefit Sustained in Long-Term Results in RCC

June 7th 2021

The frontline combination of pembrolizumab plus axitinib continued to show a survival benefit over single-agent sunitinib in patients with renal cell carcinoma.

Increased PSA Screening Reduces Prostate Cancer–Specific Mortality in Younger African Americans

May 19th 2021

An increase in the frequency of prostate-specific antigen (PSA) screening was associated with a nearly 25% reduction in prostate cancer–specific mortality in younger African Americans, according to data from a study presented in a presscast held ahead of the 2021 ASCO Annual Meeting.

Talazoparib Most Likely to Induce Response in mCRPC With Germline and/or Homozygous tDDR Alterations

April 13th 2021

Patients with heavily pretreated metastatic castration-resistant prostate cancer who have germline and/or homozygous tumor DNA damage response alterations have been shown to have a higher likelihood of responding to treatment with talazoparib.

PSMA PET Imaging Agent 18F-DCFPyL Demonstrates High CLR and PPV

February 13th 2021

February 13, 2021 - 18F-DCFPyL, an investigational prostate-specific membrane antigen PET imaging agent, was found to detect and localize metastatic lesions with a high correct localization rate and positive predictive value.

Apalutamide Plus Abiraterone Reduces Risk of Progression in mCRPC

February 11th 2021

February 11, 2021 - Adding apalutamide to abiraterone acetate and prednisone reduced the risk of radiographic progression or death by 30% in patients with chemotherapy-naïve metastatic castration-resistant prostate cancer receiving androgen deprivation therapy.

FDA Approves Multiple Companion Diagnostics for Olaparib in HRR+ mCRPC

May 20th 2020

The FDA has approved the FoundationOneCDx and BRACAnalysis CDx tests as companion diagnostics to identify patients with metastatic castration-resistant prostate cancer with homologous recombination repair mutations, making them eligible for treatment with the PARP inhibitor olaparib.

FDA Approves Frontline Atezolizumab for PD-L1–High NSCLC

May 18th 2020

The FDA has approved single-agent atezolizumab as a frontline treatment for patients with advanced non–small cell lung cancer with high PD-L1 expression.

Alvocidib Trial Launches in MDS

May 14th 2020

The first patient has been diagnosed with alvocidib, administered in sequence following azacitidine, in the expansion of the phase 1b/2 Zella 102 study in patients with myelodysplastic syndromes.

Study of Anti-CD73 Immunotherapy TJD5 in Solid Tumors Launches in China

May 13th 2020

The first patient has been dosed in a phase 1/2 trial of TJD5 in Chinese patients with advanced solid tumors, according to I-Mab, the company developing the CD73 antibody.